1.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
2.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
3.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
4.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
5.	Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
6.	Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-203, NCT01609816
7.	Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2011-204, NCT01643603
8.	CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2012-0265, NCT01664910
9.	Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201303012, NCT01747499
10.	Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: VAR0090, NCI-2012-02988, NCT01769222
11.	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 12H09, NCI-2012-03090, STU00072695, NCT01805037
12.	LMB-2 to Treat Hairy Cell Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 060150, 06-C-0150, NCI-06-C-0150, NCI-P6760, 7834, NCI-7834, NCT00337311, NCT00321555
13.	2CDA With Rituximab in Hairy Cell Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2004-0223, NCT00412594
14.	Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: BMT153, 78998, 11960, NCT00185640
15.	Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00003567, NCT00597714
16.	Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007LS072, UMN-MT2007-07, 0707M11845, UMN-2007LS072, NCT00617929
17.	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2226.00, NCI-2010-00107, P01CA078902, P01CA018029, FHCRC-2226.00, IR-6884, NCT00867529
18.	Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090005, 09-C-0005, NCT00923013
19.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
20.	T-cell Depleted Alternative Donor Transplantation Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: LCH BMT 09-01, NCT00968864
21.	Study of Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) to Treat Hematologic Malignancies and Hematopoietic Failure States Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 09-0679-04, NCT00997386
22.	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 75 Sponsor: NCI, Other Protocol IDs: 2241.00, NCI-2009-01334, P01CA078902, NCT01008462
23.	CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase: Phase II Type: Treatment Status: Active Age: 0 to 26 Sponsor: Other Protocol IDs: L 10,321, NYMC 525, NCT01049854
24.	Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100025, 10-C-0025, NCT01059786
25.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485